Early detection of left ventricular hypertrophy (LVH) is beneficial, since treatment-induced regression of LVH has been unequivocally associated with a better prognosis. Our aim was to study the relation of cardiac remodelling and natriuretic peptides (NPs) in stage 1 hypertension. We studied 175 (46 ± 7 years, 87 women and 88 men) apparently healthy middle-aged that had never been treated for hypertension. Left ventricular and atrial parameters were determined by magnetic resonance imaging. , Po0.001). In conclusion, measurement of NT-proBNP or NT-proANP does not appear to discriminate LVH in middle-aged, never treated and apparently healthy hypertensives. NT-proANP, but not NT-proBNP, reflects early cardiac remodelling in hypertensive heart disease.
Introduction
Left ventricular hypertrophy (LVH) is a common complication in hypertension and a strong predictor of cardiovascular disease. 1 Among the indices of hypertensive target-organ damage LVH is the only available marker of preclinical cardiovascular disease of which the treatment-induced regression has been unequivocally associated with a better prognosis. 2 Electrocardiographic LVH has low diagnostic accuracy in middle-aged subjects 3 and ultrasound assessment of low-and medium-risk hypertensive patients is not cost effective. 4 Patients with hypertension have been reported to have higher plasma atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) levels than normal subjects. 5 Elevated levels of natriuretic peptides (NPs) in hypertension often have been attributed to the presence of LVH. 6, 7 Although NP are not useful for community screening for LVH, 8, 9 they might be useful for the early detection of LVH in patients with essential hypertension. 7 Although the association between NP and LVH has been demonstrated in patients with severe hypertension and high prevalence of LVH, 6 ,7 the applicability of this data to patients with mild hypertension is not known. For the population at large, the greatest burden from hypertension occurs among people with only minimally elevated pressures. 10 Early and reliable detection of LVH would identify those who would have the greatest benefit from treatment and increase compliance as well. In addition, it would be essential to demonstrate the association between NP and LVH in subjects unaffected by medications, because antihypertensive drug treatment has been shown to influence NP secretion. 11 Our goal was to study the relation of magnetic resonance imaging (MRI) determined cardiac remodelling and NP in apparently healthy middle-aged with high normal or stage 1 hypertension that had never received any antihypertensive treatment.
Materials and methods

Patients and BP measurements
The recruitment procedure and home blood pressure (BP) measurements have been described in an earlier study. 3 Inclusion criteria were (a) age under 55 years, (b) participant personally believed to be hypertensive and (c) no antihypertensive treatment. All participants had a normal sinus rhythm (no signs of bundle branch block, fascicular block, preexcitation or ischaemic heart disease in electrocardiogram) and were apparently healthy. MRI was done to 188 participants and the prevalence of LVH defined by electrocardiogram when using SokolowLyon criterion was 15% (Vottonen et al.
3 ). A total of 76 participants had left ventricular mass index (LVMI), ventricular septum thickness (IVS) or left ventricular end-diastolic diameter (LVEDD) over 95% upper limits of gender-specific normal MRI reference values. 12 These 76 subjects were referred to outpatient clinic for echocardiography, which was done by one cardiologist (JM). Significant mitral valve insufficiency was detected in eight patients and significant aortic valve insufficiency in two patients. Two patients had dilated cardiomyopathy and one patient had an anamnesis of cytostatic drug treatment. These 13 patients were excluded from the study and the remaining 175 patients were included in the analysis. This study conforms to the principles outlined in the Second Declaration of Helsinki. Written informed consent was obtained from all participants and the research protocol was reviewed and approved by the ethics committee of the Kuopio University Hospital.
MRI and image analysis MRI protocol has been described in an earlier study. 3 In addition to that study, we also measured left atrial (LA) size. We used areas instead of volumes for atrial indices, because the determination of LA volumes was not feasible. LA area (LAA) was measured in long axis orientation just before opening of the mitral leaflets at the beginning of ventricular diastole. LA area index (LAAI), LVMI and IVS index (IVSI) were calculated by dividing LA area, LVM and IVS by body surface area (BSA) of the patient. LV relative wall thickness was calculated at end diastole as ((posterior wall thickness þ septal wall thickness)/LV internal diameter).
NT-proANP and NT-proBNP assays N-terminal pro-ANP (NT-proANP) and N-terminal pro-BNP (NT-proBNP) were assayed directly from 25 ml unextracted plasma. The assays utilized protocols described previously. 13 The sensitivities of the NT-proANP and NT-proBNP assays were 60 and 40 pmol l -1 plasma, respectively. The within-and between-assay coefficients of variation in each assay were o10 and o15%, respectively. The NT-proANP antiserum was raised against recombinant human proANP 1-98 and the NT-proBNP antiserum against synthetic proBNP [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 
Results
Cardiac remodelling in hypertension
Clinical characteristics are shown in Table 1 . Systolic and diastolic BP and LVMI were normally distributed. Altogether, 74 men (84%) and 72 women (83%) had systolic or diastolic BP over 135 and 85 mm Hg and were classified as hypertensives. Of the remaining 29 participants 12 had high normal BP, and 81% of the hypertensives had stage 1 hypertension. Hypertensives were same age as normotensives (43.9±6.7 years vs 46.3±6.5 years), Table 1 Clinical characteristics of the participants Table 1 ). In both women and men, NT-proANP or NT-proBNP did not correlate with BP or any of indices reflecting left ventricular remodelling in hypertensive heart disease ( Table 2 ). As our population was very homogenous in respect of LVMI and BP, we also compared the extremes of cardiac remodelling and NP levels. First, we divided participants into three groups based on their LV geometry (Figure 1 ). Subjects that had relative wall thickness under 0.45 and did not have LVH were classified as normal LV geometry (n ¼ 119, 60 women and 59 men). Subjects with concentric LV remodelling had relative wall thickness 0.45 or more and no LVH (n ¼ 25, 7 women and 18 men). Plasma levels of NT-proANP and NT-proBNP did not differ between these groups. Second, we divided participants into quartiles based on their NT-proANP and NT-proBNP levels and LVMI, IVSI, systolic BP and diastolic BP levels were compared between the lowest and highest quartiles.
All subjects with NT-proBNP level below 40 pmol l -1 were included in the low NT-proBNP group (n ¼ 96). There were no differences in LVMI, IVSI, systolic BP or diastolic BP levels between the lowest and highest quartiles (data not shown). In order to estimate the power of our study, logarithm of NTproANP was taken to make normality assumption approximately correct. In linear regression analyses, logNT-proANP did not correlate with systolic or diastolic BP or LVM (data not shown). With our sample size of 175, the power of a linear correlation to detect a correlation of 0.3 with 95% confidence is 98%. The power to detect a correlation of 0.2 is 76%. (Figure 1 ).
Discussion
Our study shows that in never treated apparently healthy middle-aged subjects NT-proANP and NTproBNP do not correlate with left ventricular remodelling. Plasma levels of NP did not correlate with BP, which supports the finding that plasma BNP and NT-proBNP levels are not elevated in stage 1 hypertension. 15 However, NT-proANP correlated with LA size, but not with LVMI. This suggests that NTproANP reflects early cardiac remodelling, that is, level of diastolic stiffness in hypertensive heart disease, and thus NT-proANP is an earlier marker of cardiac remodelling than NT-proBNP. In addition, we confirm previous studies showing that NT-proANP correlates positively with age and negatively with BMI, and is higher in women than in men. [16] [17] [18] The most controversial finding of this study is that plasma levels of NT-proANP and NT-proBNP were not increased in subjects with definite LVH. It has been demonstrated that levels of NP are elevated in severe hypertension, but not in mild hypertension. 5, 7, 15, 19 Cardiac myocyte stretch causes both LVH 20 and increased secretion of NP. 21, 22 Therefore, the reported correlation between NP and LVH in patients with severe hypertension and high prevalence of LVH could be due to factors related to LVH, such as myocardial fibrosis and diastolic dysfunction. 23 In this study, never treated middleaged subjects had high normal or stage 1 hypertension. Despite mild hypertension, they clearly had increased left ventricular indices in comparison with published gender-specific normal adult MRI reference values, 12 and 13% men and 23% women had LVH. In addition, we have demonstrated earlier that LVMI correlates with electrocardiogram LVH criteria (Sokolow-Lyon voltage, Cornell voltage, Sokolow-Lyon product and Cornell product) and that these electrocardiogram criteria for LVH have a low but significant discrimination ability in these subjects. 3 We found no correlation between NTproANP/NT-proBNP and left ventricular indices and subjects with the highest and lowest plasma NTproANP/NT-proBNP levels had similar LVMI and IVSI demonstrating that LVH per se does not cause increased NP secretion. This finding is supported by population-based studies, where subjects with LVH or left ventricular systolic dysfunction have been shown to have increased levels of NP, but NP have not been reported to correlate with BP or LVM. 8, 9, 24 Furthermore, plasma BNP levels are not increased in cyclists with significant LVH, 25 and we have shown that most of the patients with non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the a-tropomyosin gene and marked LVH have normal plasma NT-proBNP levels. 26 Although LA size is an independent predictor of cardiovascular mortality and morbidity, 27, 28 the mechanism of the LA enlargement remains poorly elucidated. Normal aging does not increase LA size until the eight decade, and there are no sex-related differences in indexed LA areas. 29, 30 LA size has been hypothesized to be a marker of diastolic function, because LA volume increases with increasing severity of diastolic dysfunction. 31, 32 Findings that regression of electrocardiographic LVH is associated with a decrease in new-onset atrial fibrillation independent of BP 33 and that LA size is related to left ventricular ventricular mass 34 suggest that left ventricular remodelling could be associated with LA remodelling as well. ANP is mainly synthesized in the atria of the normal adult heart, but ventricular hypertrophy is characterized by an augmentation of the ANP synthesis in the ventricle. 35 In our study, NT-proANP correlated with LAAI in both men and women, although there was no correlation between NT-proANP and LVMI. Natriuretic peptides in hypertensive heart disease N Partanen et al As myocyte stretch is the major determinant of ANP secretion, 21 left ventricular diastolic dysfunction could explain the observed association between NT-proANP and LAAI. Assessment of diastolic function was not feasible in our MRI imaging protocol, but there is some indirect data to support this hypothesis. Women had higher NT-proANP levels, LAAI and prevalence of LVH than men. Redfield et al. 36 have shown that female gender is associated with increases in vascular and ventricular systolic and diastolic stiffness even in the absence of cardiovascular disease. They demonstrated that estimates of LA pressure and diastolic elastance were higher in women than in men. In this study, women and men were the same age and had similar BP levels and BMI. Therefore, difference in the left ventricular diastolic function could explain the observed higher levels of NT-proANP in women. Our results suggest that LA enlargement is an early finding in hypertension and NT-proANP level reflects the enlargement of the left atrium. This may explain why increased levels of NT-proANP are related to increased risk of atrial fibrillation in the population. 37 NT-proANP could be a sensitive marker of diastolic dysfunction, but this needs to be examined in future studies.
The whole study population represents well middle-aged patients in the primary care, where new tools for detection of LVH in the assessment of hypertensive patients are needed. Our study shows that plasma NT-proANP or NT-proBNP levels have no discrimination ability for LVH in middle-aged subjects, and measurement of NP should not be used to diagnose or suspect LVH. In conclusion, our findings suggest that that LVH per se does not cause increased NP secretion and that in hypertensive heart disease NT-proANP is a more sensitive marker of cardiac remodelling than NT-proBNP. It is plausible that LA enlargement itself does not cause increased ANP secretion, but ANP reflects LA pressure overload secondary to diastolic dysfunction.
What is known about topic K Cardiac myocyte stretch causes both LVH and increased secretion of natriuretic peptides, and plasma natriuretic peptide levels are increased with LVH in patients with severe hypertension and high prevalence of LVH. K Although no clear relationship between plasma natriuretic peptide levels and LVH has been reported, it is generally believed that natriuretic peptides correlate with left ventricular mass and blood pressure.
What this study adds K In never treated apparently healthy middle-aged with high normal or stage 1 hypertension levels of NT-proANP and NT-proBNP are similar to healthy subjects and they do not correlate with left ventricular remodelling. K NT-proANP correlates with left atrial size, suggesting that left atrial enlargement is an early finding in hypertension. NT-proANP could be a sensitive marker of diastolic left ventricular dysfunction.
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